DiaMedica Therapeutics Inc. (DMAC )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DMAC
- Company DiaMedica Therapeutics Inc.
- Price $6.41
- Changes Percentage 31.62
- Change 1.54
- Day Low $4.75
- Day High $6.41
- Year High $6.41
- Year Low $2.14
- Market Cap $274,095,446
- Price Avg 50 EMA (D) $4.65
- Price Avg 200 EMA (D) $3.59
- Exchange NASDAQ
- Volume 216,386
- Average Volume 82,842
- Open $4.76
- Previous Close $4.87
- EPS -0.56
- PE -11.45
- Earnings Announcement 2025-03-17 10:00:00
- Shares Outstanding $42,760,600
Company brief: DIAMEDICA THERAPEUTICS INC. (DMAC )
- Healthcare
- Biotechnology
- Mr. Dietrich John Pauls MBA
- https://www.diamedica.com
- US
- N/A
- 08-03-2012
- CA25253X2077
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.